B-cell Acute Lymphoblastic Leukemia Clinical Trials

16 studies are recruiting for b-cell acute lymphoblastic leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

   The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will comp…

   Stage

   Phase 3

   Ages

   1 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   6 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07223021 on ClinicalTrials.gov

3. UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

   This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.

   Stage

   Phase 1

   Ages

   0 to 30

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Run by

   University of Colorado, Denver

   See if you can join NCT04544592 on ClinicalTrials.gov

4. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   H. Lee Moffitt Cancer Center, Tampa, Florida

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

5. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

   This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

   Stage

   Phase 2

   Ages

   7 to 25

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   16 in total

   Run by

   Etan Orgel

   See if you can join NCT05082519 on ClinicalTrials.gov

6. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   City of Hope, Duarte, California

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

7. Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

   This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targeting the B cell surface antigens CD19/20/22 following admini…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kansas Cancer Center, Westwood, Kansas

   Run by

   University of Kansas Medical Center

   See if you can join NCT06879340 on ClinicalTrials.gov

8. Co-administration of CART22-65s and huCART19 for B-ALL

   This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).

   Stage

   Phase 1

   Ages

   Up to 29

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Stephan Grupp MD PhD

   See if you can join NCT05674175 on ClinicalTrials.gov

9. A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

   The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine child…

   Stage

   Not phased

   Ages

   1 to 23

   Site

   Arkansas Children's, Little Rock, Arkansas

   Locations

   2 in total

   Run by

   Arkansas Children's Hospital Research Institute

   See if you can join NCT07422337 on ClinicalTrials.gov

10. Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

    The goal of this clinical trial is to learn if the combination of drugs Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone (IoVeX) are safe to treat relapsed B-cell Acute Lymphoblastic Leukemia (B-ALL) in pediatric and adult patients. It will also learn if these drugs are well tolerated. The main…

    Stage

    Phase 1

    Ages

    1 to 39

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06863259 on ClinicalTrials.gov

11. CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

    This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

    Stage

    Phase 1

    Ages

    0 to 30

    Site

    Children's Hospital Colorado, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT06559189 on ClinicalTrials.gov

12. ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

    This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Locations

    4 in total

    Run by

    Marlise Luskin, MD

    See if you can join NCT03595917 on ClinicalTrials.gov

13. Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

    This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the…

    Stage

    Phase 1

    Ages

    15 to 50

    Site

    University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California

    Locations

    19 in total

    Run by

    Cellectis S.A.

    See if you can join NCT04150497 on ClinicalTrials.gov

14. The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

    This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL…

    Stage

    Phase 2

    Ages

    1 to 25

    Site

    Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham, Alabama

    Locations

    24 in total

    Run by

    Pediatric Transplantation & Cellular Therapy Consortium

    See if you can join NCT03509961 on ClinicalTrials.gov

15. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

    Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    5 in total

    Run by

    Vincerx Pharma, Inc.

    See if you can join NCT06034275 on ClinicalTrials.gov

16. Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

    This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, whi…

    Stage

    Phase 2

    Ages

    Up to 25

    Site

    Children's Hospital of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT04746209 on ClinicalTrials.gov